(NASDAQ:XENE) shares saw heavy trading volume with 130K shares changing hands on Tuesday. Volume was up 87.38% over the stocks average daily volume.
Short traders are feeling a little more bullish on shares of Xenon Pharmace Cm Sh recently if you pay attention to the change in short interest. The company had a fall in short interest of -6.55% between September 29, 2017 and October 13, 2017. Short interest fell from 152,341 to 142,358 over that timeframe. The days to cover decreased to 5.0 and the short interest percentage is 0.01% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (XENE). Kcg Holdings, Inc. reduced its ownership by shedding 7,040 shares a decrease of 23.2% from 03/31/2017 to 06/30/2017. Kcg Holdings, Inc. currently owns 23,367 shares with a value of $74,000. The value of the position overall is down by 39.3%. As of quarter end Sabby Management, LLC had acquired 14,330 shares growing its holdings by 4.8%. The value of the total investment in Xenon Pharmace Cm Sh decreased from $1,186,000 to $979,000 a change of $207,000 quarter to quarter.
Alyeska Investment Group, L.p. grew its investment by buying 1,366 shares an increase of 0.3% as of 06/30/2017. Alyeska Investment Group, L.p. now holds 441,260 shares valued at $1,390,000. The total value of its holdings decreased 21.0%. Bank Of Montreal /can/ cut its holdings by shedding 2,250 shares a decrease of 40.7%. Bank Of Montreal /can/ now controls 3,280 shares worth $10,000. The value of the position overall is down by 41.2%.
Equity analyst Jefferies Group LLC updated coverage of XENE and giving a rating of “Buy” and setting a price target of $5.00.
The company is now down from yesterday’s close of 2.25. The company currently has a P/E ratio of N/A and the market cap of the company is 39.60M. In the last earnings report the EPS was $-1.67 with 18.00M shares now outstanding.
Xenon Pharmaceuticals Inc. (Xenon), launched on May 17, 2000, is a clinical-stage biopharmaceutical company. The Company is involved in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes Glybera, TV-45070, GDC-0310 and XEN901 (Nav1.6 inhibitor). Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans. Its platform is built on the foundation of identifying and studying rare individuals and families with severe phenotypes to discover single-gene defects that have biological effects in humans..